Skip to main content Skip to search Skip to main navigation

EUDRAGMDP: EMA with important information for all users

As communicated by the EMA, the EUDRAGMDP database will be „merged“ with EMA’s Organisation Management Service (OMS). This is an important change to be aware of for all manufacturers, importers and distributors of human and veterinary medicines whose information is recorded in EUDRAGMDP.

They must ensure that their sites are registered in OMS. As of 28 January 2022, before applying for a new or updated manufacturing or wholesale distribution authorisation with national competent authorities, a correct registration in OMS is mandatory.

What makes this step necessary?

The new regulatory framework for veterinary medicines (Regulations 2019/6 and 2021/16 and Article 9(h)) thereof, requires changes to the EudraGMDP database. Those will become effective as of 28 January 2022.

EMA will organize a webinar on the OMS services for interested manufacturers, importers and distributors on 12 October 2021 at 14:00 – 16:30 CEST. Participants will have the chance to ask questions and seek clarifications on OMS services and activities. Interested participants should register by 5 October. The webinar will be recorded and published on EMA’s website later on.


EMA: OMS

Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be interested in the following articles:

EMA: Scientific Guideline on Development and Manufacture of Synthetic Peptides

EMA: Scientific Guideline on Development and Manufacture of Synthetic Peptides

The EMA has published the final version of the scientific guideline „Development and manufacture of synthetic peptides“.
Read more
EU: Strengthening Pharmaceutical Supply Chains and Global Health Resilience

EU: Strengthening Pharmaceutical Supply Chains and Global Health Resilience

The European Commission has published a new communication on reinforcing global health resilience, with a strong focus on resilient pharmaceutical supply chains, expanded manufacturing capacity, and security of supply for critical health products.
Read more
Annex 22: EMA Workshop on AI in GMP

Annex 22: EMA Workshop on AI in GMP

The European Medicines Agency (EMA) will hold a two-day multistakeholder workshop on 30 June and 1 July 2026 to gather expert input for the development of Annex 22 of the EU GMP Guide on the use of artificial intelligence (AI) in medicines manufacturing.
Read more
EU: Commission Implementing Regulation on QM and Conformity Assessment Activities of Notified Bodies

EU: Commission Implementing Regulation on QM and Conformity Assessment Activities of Notified Bodies

Commission Implementing Regulation (EU) 2026/977 of 4 May 2026 further specifies requirements for notified bodies under the MDR and IVDR frameworks and aims to promote a more harmonised implementation across the European Union.
Read more
FDA: Pilot Program for One-Day Inspectional Assessments

FDA: Pilot Program for One-Day Inspectional Assessments

Since April 2026, the U.S. FDA has been piloting “One-Day Inspectional Assessments” as a complement to standard FDA inspections.
Read more
The ABC of User Requirements Specification (URS)

The ABC of User Requirements Specification (URS)

In the URS, the future user defines what the system should be capable of, but also what it is limited to. In addition to the (testable!) technical requirements, regulatory require-ments should also be taken into account.
Read more
Previous
Next